Loading...
XPARMAAT
Market cap113mUSD
Dec 24, Last price  
7.94EUR
1D
0.00%
1Q
8.24%
IPO
-42.48%
Name

Maat Pharma SA

Chart & Performance

D1W1MN
XPAR:MAAT chart
P/E
—
P/S
49.51
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
61.57%
Rev. gr., 5y
20.09%
Revenues
2m
+55.80%
109,320892,00089,3040972,0001,430,0002,228,000
Net income
-20m
L+42.16%
-3,858,412-4,546,000-6,647,000-5,350,000-9,140,000-13,870,000-19,717,000
CFO
-19m
L+48.12%
0-3,871,000-5,019,000-5,814,000-7,929,000-12,605,000-18,670,000

Profile

MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.
URL
https://www.maatpharma.com/
IPO date
Nov 08, 2021
Employees
43
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
2,228
55.80%
1,430
47.12%
972
 
Cost of revenue
23,871
16,627
10,695
Unusual Expense (Income)
NOPBT
(21,643)
(15,197)
(9,723)
NOPBT Margin
Operating Taxes
157
121
Tax Rate
NOPAT
(21,643)
(15,354)
(9,844)
Net income
(19,717)
42.16%
(13,870)
51.75%
(9,140)
70.84%
Dividends
Dividend yield
Proceeds from repurchase of equity
12,513
(35)
32,435
BB yield
-15.77%
0.04%
-100.13%
Debt
Debt current
2,223
2,987
1,254
Long-term debt
15,815
9,020
5,317
Deferred revenue
Other long-term liabilities
323
323
309
Net debt
(6,276)
(23,740)
(36,971)
Cash flow
Cash from operating activities
(18,670)
(12,605)
(7,929)
CAPEX
(1,093)
(662)
(238)
Cash from investing activities
(440)
(815)
(238)
Cash from financing activities
8,141
5,364
31,558
FCF
(29,266)
(15,280)
(10,088)
Balance
Cash
24,314
35,311
43,304
Long term investments
436
238
Excess cash
24,203
35,676
43,493
Stockholders' equity
(16,695)
(11,513)
(6,608)
Invested Capital
50,327
49,962
52,545
ROIC
ROCE
EV
Common stock shares outstanding
11,365
9,892
2,427
Price
6.98
-12.75%
8.00
-40.07%
13.35
 
Market cap
79,328
0.24%
79,134
144.29%
32,394
 
EV
73,052
55,394
(4,577)
EBITDA
(20,772)
(14,768)
(9,395)
EV/EBITDA
0.49
Interest
402
185
121
Interest/NOPBT